Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

Michael D. Arensman,Xiaoran S. Yang,Danielle M. Leahy,Lourdes Toral-Barza,Mary Mileski,Edward C. Rosfjord,Fang Wang,Shibing Deng,Jeremy S. Myers,Robert T. Abraham,Christina H. Eng
DOI: https://doi.org/10.1073/pnas.1814932116
IF: 11.1
2019-04-24
Proceedings of the National Academy of Sciences
Abstract:Significance xCT, the cystine–glutamate antiporter, has been implicated in supporting both tumor growth and T cell proliferation; thus, antitumor effects of systemic xCT inhibition may be blunted by compromised antitumor immunity. This report details the unexpected finding that xCT is dispensable for T cell proliferation in vivo and for antitumor immune responses. Consequently, tumor cell xCT loss acts synergistically with the immunotherapeutic agent anti–CTLA-4, laying the foundation for utilizing specific xCT inhibitors clinically to expand the efficacy of existing anticancer immunotherapeutics.
What problem does this paper attempt to address?